Verrica Pharmaceuticals (VRCA)
Commercializes YCANTH for molluscum while developing additional dermatology treatments.
Something off on this page? Send us feedback.
Commercializes YCANTH, a professionally administered cantharidin drug-device combination for molluscum contagiosum in the United States. The single-product commercial base is paired with a global common-warts program, Japanese collaboration with Torii, and VP-315, a licensed dermatologic-oncology candidate.
Commercializes YCANTH, a proprietary single-use applicator that combines cantharidin with a drug-device format, for molluscum contagiosum. The product is administered by healthcare professionals in the United States, while a global late-stage program is testing it for common warts.
VP-315, or ruxotemitide, is a licensed intratumoral oncolytic peptide immunotherapy being developed for dermatologic oncology, initially targeting basal-cell and squamous-cell carcinomas. Torii has Japanese approval for YCANTH, known there as TO-208.
The operating model combines U.S. YCANTH commercialization with clinical label expansion and licensed pipeline development. It depends on regulatory review, third-party manufacturing quality, professional administration, distributor and pharmacy access, and the Torii collaboration.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Target |
|---|---|---|---|---|---|
| Aug 27, 2026 | Lake Street | Initiate | Buy | $9 | |
| Dec 18, 2025 | Loop Capital Markets | Target | $17 | ||
| Dec 18, 2025 | Brookline Capital | Upgrade | Hold | Buy | |
| Nov 6, 2024 | HC Wainwright & Co. | Downgrade | Buy | Neutral | |
| Nov 5, 2024 | RBC Capital | Downgrade | Outperform | Sector Perform |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $11.2M · Total debt $1.8M · Total assets $36.0M · Shareholders' equity $4.3M
- Revenue
- $5.9M
- Operating income
- −$13.1M
- Net income
- −$13.2M
No dividends on record.
| Institutions39 holders · as of Mar 31, 2026 | 27.81% | 4.78M shares | |
| Insiders12 holders · as of Aug 18, 2026 | 50.06% | 8.60M shares | |
| Otherremainder | 22.13% | 3.80M shares |
17.18M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Paul B. ManningInsiderdirector, 10 percent owner | 46.90% | 8.06M | 13Dfiled Nov 28, 2025 ↗ |
Caligan Partners LPInstitution | 5.38% | 923,910 | 13Fas of Mar 31, 2026 |
Affinity Asset Advisors, LLCInstitution | 4.12% | 707,338 | 13Fas of Mar 31, 2026 |
Cannell Capital LLCInstitution | 3.99% | 685,123 | 13Fas of Mar 31, 2026 |
Armistice Capital, LLCInstitution | 3.02% | 518,181 | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 18, 2026 | John J. Kirby | officer: Interim CFO | +5,000 | $4.93 |
| Aug 18, 2026 | Noah L. Rosenberg | officer: CMO | +2,030 | $4.92 |
| Aug 17, 2026 | Noah L. Rosenberg | officer: CMO | +4,200 | $4.91 |
| Aug 17, 2026 | Jayson Rieger | director, officer: CEO and President | +5,000 | $4.91 |
| Aug 14, 2026 | Jayson Rieger | director, officer: CEO and President | +20,000 | $5.06 |
- Pelthos Therapeutics
At-home topical molluscum therapy in direct competition with YCANTH
- Regeneron
Advanced BCC and CSCC immunotherapy alongside VP-315 development
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Verrica Pharmaceuticals | $5.42 | +3.44% | $92.6M | — | — | 3.1 | −53.9% |
| Pelthos Therapeutics | $25.91 | +3.56% | $87.0M | — | — | 2.0 | — |
| Regeneron | $850.48 | −0.18% | $87.78B | 21.1 | 14.1 | 5.7 | +16.7% |
| Median | 21.1 | 14.1 | 3.8 | +16.7% |